Scholars@Duke
Joe Brice Weinberg

Joe Brice Weinberg

Professor Emeritus of Medicine
Medicine, Hematology
weinb001@duke.edu
Duke Box 3396, Durham, NC 27708
E1006 VA Med Ctr, 508 Fulton St, Durham, NC 27705

Scholarly Works - Conferences

Novel Prognostic Markers in Previously Treated Chronic Lymphocytic Leukemia

Conference Blood · November 5, 2021 AbstractBackground: We need new biomarkers that manage CLL patients receiving novel chemotherapeutic agent treatments. In our earlier pilot study, we reported an association of inferior outcomes in those wit ... Full text Cite

Abstract 2209: Characterization of underlying genomic features among African ancestry populations diagnosed with chronic lymphocytic leukemia

Conference Cancer Research · July 1, 2021 AbstractChronic lymphocytic leukemia (CLL) is a neoplastic disease of mature B-cells with a highly heterogeneous clinical course. While European ancestry (EA) populations present an increased incidence of CL ... Full text Cite

Alpha Globin Copy Number and Exhaled Nitric Oxide in Black Individuals

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · 2020 Link to item Cite

THE IMPACT OF ALPHA-GLOBIN GENE VARIANTS ON ENDOTHELIAL FUNCTION IN ADULTS WITH SEVERE MALARIA

Conference AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE · January 1, 2019 Link to item Cite

Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients

Conference Blood · November 29, 2018 AbstractIntroduction Exercise has potent immune enhancing and anti-inflammatory effects in healthy adults, and is increasingly recognized as a beneficial adjunct to cancer care. Incr ... Full text Cite

DO ALPHA GLOBIN GENE VARIANTS AFFECT ENDOTHELIAL FUNCTION IN PATIENTS WITH SEVERE MALARIA?

Conference AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE · January 1, 2018 Link to item Cite

Ruxolitinib in treatment of refractory hypereosinophilic syndrome.

Conference Journal of Clinical Oncology · March 1, 2017 73 Background: Hypereosinophilic syndrome (HES) is a rare hematologic disorder in which the eosinophils proliferate and infiltrate and damage multiple organs. Without treatment, the condition is fatal, usually due to cardiac dysf ... Full text Cite

Ruxolitinib Used to Treat Hypereosinophilic Syndrome

Conference Blood · December 2, 2016 AbstractIntroduction: Hypereosinophilic syndrome (HES) is a rare hematologic disorder in which the eosinophils proliferate and infiltrate and damage multiple organs. Without treatment, the condition is fatal ... Full text Cite

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

Conference Blood · December 2, 2016 AbstractINTRODUCTION:Conventional treatment of acute myeloid leukemia (AML) remains largely unchanged for over thirty years. With poor overall survival and disease cure rates ... Full text Cite

Surface CD5 Protein Risk Stratifies Chronic Lymphocytic Leukemia

Conference Blood · December 2, 2016 AbstractIntroduction: Chronic Lymphocytic Leukemia (CLL) is a malignancy characterized by B-lymphocytes with aberrant expression of CD5. In normal T-lymphocytes, CD5 is an important regulator of T-cell recep ... Full text Cite

INCREASED TOTAL BODY ARGININE FLUX AND DECREASED NITRIC OXIDE SYNTHESIS IN SEVERE FALCIPARUM MALARIA

Conference AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE · October 1, 2015 Link to item Cite

Abstract A24: The dual PI3K δ/γ inhibitor, RP6530, in combination with ibrutinib or fludarabine, synergistically enhances cytotoxicity in primary CLL cells in vitro.

Conference Clinical Cancer Research · September 1, 2015 AbstractBackground: The PI3K pathway is a central pro-survival mechanism in chronic lymphocytic leukemia (CLL). While the delta isoform of PI3K is largely associated with B-cell signaling, gamma is involved ... Full text Cite

Abstract 4518: The PI3K-δ inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro

Conference Cancer Research · October 1, 2014 AbstractBackground: The PI3K pathway is a central pro-survival mechanism in chronic lymphocytic leukemia (CLL), with expression of the delta isoform of PI3K largely restricted to lymphocytes. Clinical evalua ... Full text Cite

Molecular and Clinical Associations Between Vitamin D and Chronic Lymphocytic Leukemia

Conference Blood · November 15, 2013 AbstractIntroductionVitamin D deficiency is common in the general population. Approximately 25-50% of adult patients seen at routine v ... Full text Cite

CD38 Variation in Chronic Lymphocytic Leukemia

Conference Blood · November 16, 2012 AbstractAbstract 4576Background:Chronic lymphocytic leukemia (CLL) has a highly variable clinical cou ... Full text Cite

The Metabolic Signature of CLL: Enhanced Glucose Metabolism in A Subset of High-Risk CLL Patients

Conference Blood · November 16, 2012 AbstractAbstract 1785Background:Chronic lymphocytic leukemia (CLL), the most common hematopoietic mal ... Full text Cite

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Conference Blood · November 20, 2009 AbstractAbstract 802Background and Significance:Even though we have treatments for CLL, it remains an ... Full text Cite

MAM 2008 Poster Abstracts

Conference International Journal for Parasitology · January 2008 Full text Cite

A Genomic Strategy To Refine Prognosis and Predict Response to Therapy in Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractChronic Lymphocytic Leukemia (CLL) is notable for variation in aggressiveness of disease. Many patients with low-risk disease at diagnosis can be followed expectantly, while others rapidly require th ... Full text Cite

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

Conference Blood · November 16, 2007 AbstractB cell chronic lymphocytic leukemia (CLL), the most common subtype of leukemia in the United States of America and in Europe, is treatable but incurable. New drugs are needed for its management. Phos ... Full text Cite

Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractSurvival of CLL cells requires sustained activation of the anti-apoptotic PI-3-kinase/Akt pathway, and many therapies for CLL cause leukemia cell death by triggering apoptosis. Blood lipoprotein part ... Full text Cite

Monoclonal B Cell Lymphocytosis Exhibits Biologic Diversity Similar to Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractBackground: Monoclonal B cell lymphocytosis (MBL) is a pre-clinical syndrome characterized by small accumulations of monoclonal B lymphocytes in the peripheral blood. MBL have an immunophenotype simi ... Full text Cite

Functional and Numerical T Cell Abnormalities in Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractBackground: Although most malignancies are associated with decreased numbers of circulating T cells, in CLL they are elevated 2 to 4 times normal. Rather than promoting an anti-tumor response, this i ... Full text Cite

Monoclonal B Cell Lymphocytosis as a Marker of Inherited Predisposition to Chronic Lymphocytic Leukemia.

Conference Blood · November 16, 2007 AbstractBackground: Segregation analyses suggest that CLL has one of the highest inherited risks among all types of cancer. However, no common germline mutations that confer an inherited predisposition to CL ... Full text Cite

Cobalamins and Cobinamides Inhibit Nitric Oxide Synthase Enzymatic Activity.

Conference Blood · November 16, 2005 AbstractCobalamins (Cbl) serve as important co-factors for methionine synthase and methylmalonyl-coA mutase. They also can block the activities of nitric oxide (NO), as the cobalt binds NO and quenches its b ... Full text Cite

Oxygen, mechanical compression and inflammation in articular cartilage.

Conference JOURNAL OF BONE AND MINERAL RESEARCH · October 1, 2004 Link to item Cite